An update to the American Radium Society's appropriate use criteria of lower grade gliomas: Integration of IDH inhibitors

Martin C. Tom; Seema Nagpal; Joshua D. Palmer; William G. Breen; Erqi L. Pollom; Eric J. Lehrer; Tresa M. McGranahan; Kevin Shiue; Anupama Chundury; Shearwood McClelland; Hina Saeed; Eric L. Chang; Veronica L.S. Chiang; Tony J.C. Wang; Jonathan P.S. Knisely; Samuel T. Chao; Michael T. Milano

doi:10.1016/j.radonc.2024.110640

An update to the American Radium Society's appropriate use criteria of lower grade gliomas: Integration of IDH inhibitors

Martin C. Tom
, Seema Nagpal
, Joshua D. Palmer
, William G. Breen
, Erqi L. Pollom
, Eric J. Lehrer
, Tresa M. McGranahan
, Kevin Shiue
, Anupama Chundury
, Shearwood McClelland
, Hina Saeed
, Eric L. Chang
, Veronica L.S. Chiang
, Tony J.C. Wang
, Jonathan P.S. Knisely
, Samuel T. Chao
, Michael T. Milano

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The ARS brain committee recommends that vorasidenib may be appropriate for recurrent or residual IDH-mutant grade 2 oligodendroglioma or astrocytoma. Vorasidenib is usually not appropriate for completely resected grade 2 oligodendroglioma or astrocytoma, any grade 3 oligodendroglioma or astrocytoma, or combined with radiotherapy and/or chemotherapy for any grade 2–3 glioma.

Original language	English
Article number	110640
Journal	Radiotherapy and Oncology
Volume	202
DOIs	https://doi.org/10.1016/j.radonc.2024.110640
State	Published - Jan 2025
Externally published	Yes

Keywords

Astrocytoma
Grade 2 glioma
IDH inhibitor
Oligodendroglioma
Vorasidenib

Access to Document

10.1016/j.radonc.2024.110640

Cite this

Tom, M. C., Nagpal, S., Palmer, J. D., Breen, W. G., Pollom, E. L., Lehrer, E. J., McGranahan, T. M., Shiue, K., Chundury, A., McClelland, S., Saeed, H., Chang, E. L., Chiang, V. L. S., Wang, T. J. C., Knisely, J. P. S., Chao, S. T., & Milano, M. T. (2025). An update to the American Radium Society's appropriate use criteria of lower grade gliomas: Integration of IDH inhibitors. Radiotherapy and Oncology, 202, Article 110640. https://doi.org/10.1016/j.radonc.2024.110640

@article{d780f3823c474ce096d0edf850117502,

title = "An update to the American Radium Society's appropriate use criteria of lower grade gliomas: Integration of IDH inhibitors",

abstract = "The ARS brain committee recommends that vorasidenib may be appropriate for recurrent or residual IDH-mutant grade 2 oligodendroglioma or astrocytoma. Vorasidenib is usually not appropriate for completely resected grade 2 oligodendroglioma or astrocytoma, any grade 3 oligodendroglioma or astrocytoma, or combined with radiotherapy and/or chemotherapy for any grade 2–3 glioma.",

keywords = "Astrocytoma, Grade 2 glioma, IDH inhibitor, Oligodendroglioma, Vorasidenib",

author = "Tom, \{Martin C.\} and Seema Nagpal and Palmer, \{Joshua D.\} and Breen, \{William G.\} and Pollom, \{Erqi L.\} and Lehrer, \{Eric J.\} and McGranahan, \{Tresa M.\} and Kevin Shiue and Anupama Chundury and Shearwood McClelland and Hina Saeed and Chang, \{Eric L.\} and Chiang, \{Veronica L.S.\} and Wang, \{Tony J.C.\} and Knisely, \{Jonathan P.S.\} and Chao, \{Samuel T.\} and Milano, \{Michael T.\}",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier B.V.",

year = "2025",

month = jan,

doi = "10.1016/j.radonc.2024.110640",

language = "English",

volume = "202",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

}

Tom, MC, Nagpal, S, Palmer, JD, Breen, WG, Pollom, EL, Lehrer, EJ, McGranahan, TM, Shiue, K, Chundury, A, McClelland, S, Saeed, H, Chang, EL, Chiang, VLS, Wang, TJC, Knisely, JPS, Chao, ST & Milano, MT 2025, 'An update to the American Radium Society's appropriate use criteria of lower grade gliomas: Integration of IDH inhibitors', Radiotherapy and Oncology, vol. 202, 110640. https://doi.org/10.1016/j.radonc.2024.110640

TY - JOUR

T1 - An update to the American Radium Society's appropriate use criteria of lower grade gliomas

T2 - Integration of IDH inhibitors

AU - Tom, Martin C.

AU - Nagpal, Seema

AU - Palmer, Joshua D.

AU - Breen, William G.

AU - Pollom, Erqi L.

AU - Lehrer, Eric J.

AU - McGranahan, Tresa M.

AU - Shiue, Kevin

AU - Chundury, Anupama

AU - McClelland, Shearwood

AU - Saeed, Hina

AU - Chang, Eric L.

AU - Chiang, Veronica L.S.

AU - Wang, Tony J.C.

AU - Knisely, Jonathan P.S.

AU - Chao, Samuel T.

AU - Milano, Michael T.

PY - 2025/1

Y1 - 2025/1

N2 - The ARS brain committee recommends that vorasidenib may be appropriate for recurrent or residual IDH-mutant grade 2 oligodendroglioma or astrocytoma. Vorasidenib is usually not appropriate for completely resected grade 2 oligodendroglioma or astrocytoma, any grade 3 oligodendroglioma or astrocytoma, or combined with radiotherapy and/or chemotherapy for any grade 2–3 glioma.

AB - The ARS brain committee recommends that vorasidenib may be appropriate for recurrent or residual IDH-mutant grade 2 oligodendroglioma or astrocytoma. Vorasidenib is usually not appropriate for completely resected grade 2 oligodendroglioma or astrocytoma, any grade 3 oligodendroglioma or astrocytoma, or combined with radiotherapy and/or chemotherapy for any grade 2–3 glioma.

KW - Astrocytoma

KW - Grade 2 glioma

KW - IDH inhibitor

KW - Oligodendroglioma

KW - Vorasidenib

UR - https://www.scopus.com/pages/publications/85209675438

U2 - 10.1016/j.radonc.2024.110640

DO - 10.1016/j.radonc.2024.110640

M3 - Article

AN - SCOPUS:85209675438

SN - 0167-8140

VL - 202

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

M1 - 110640

ER -

An update to the American Radium Society's appropriate use criteria of lower grade gliomas: Integration of IDH inhibitors

Abstract

Keywords

Access to Document

Fingerprint

Cite this